ARIAD Pharmaceuticals Inc logo

ARIA - ARIAD Pharmaceuticals Inc Share Price

$23.99 0.0  0.0%

Last Trade - 15/02/17

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £142.4m
Position in Universe th / 6416
Bullish
Bearish
Unlock ARIA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARIA Revenue Unlock ARIA Revenue

Net Income

ARIA Net Income Unlock ARIA Revenue

Normalised EPS

ARIA Normalised EPS Unlock ARIA Revenue

PE Ratio Range

ARIA PE Ratio Range Unlock ARIA Revenue

Dividend Yield Range

ARIA Dividend Yield Range Unlock ARIA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARIA EPS Forecasts Unlock ARIA Revenue
Profile Summary

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Directors
Last Annual December 31st, 2015
Last Interim September 30th, 2016
Incorporated April 12, 1991
Public Since May 20, 1994
No. of Shareholders: 288
No. of Employees: 459
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 194,200,862
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARIA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to ARIA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.